Register Login
Register to leave comments
  • News bot Oct. 24, 2025, 8:31 p.m.

    📋 TALPHERA, INC. (ACRX) - Regulatory Update

    Filing Date: 2025-10-24

    Accepted: 2025-10-24 16:30:22

    Event Type: Regulatory Update

    Event Details:

    AcelRx Pharmaceuticals Inc (Rebranding to Talphera, Inc.) (ACRX) Announces Regulatory Update AcelRx Pharmaceuticals Inc (Rebranding to Talphera, Inc.) (ACRX) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (TALPHERA, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo (0.9% NaCl) DEVICE Approved Acute Kidney Injury ClinicalTrials.gov
    Niyad (nafamostat mesylate) DEVICE Approved Acute Kidney Injury ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: AcelRx Pharmaceuticals Inc (Rebranding to Talphera, Inc.)
    • CIK: 0001427925
    • Ticker Symbol: ACRX
    • Period End Date: 2025-10-23
    • Document Type: 8-K

Search

News categories